Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study

Dehpouri, Tannaz;Rokni, Ghasem Rahmatpour;Narenjbon, Nematollah Ahangar;Goldust, Mohamad;Yamauchi, Paul S;Wollina, Uwe;Lotti, Torello;Kircik, Leon;Lernia, Vito Giuseppe Di;Sonthalia, Sidharth;Vojvodic, Aleksandra;Szepietowski, Jacek;Bahadoran, Philippe;Errichetti, Enzo;Cantisani, Carmen;Atzori, Laura

Member of the Collaboration Group

;Rezaee, Elham;Kutlubay, Zekayi;Engin, Burhan;Nisticò, Steven;Damiani, Giovanni;Conic, Rosalynn R Z;Goren, Andy;Čabrijan, Leo;Tchernev, Georgi

2019-01-01

---

Abstract

Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes.